French drug industry kicked off key government committee
This article was originally published in SRA
Executive Summary
The French drug industry body Leem is to lose its seat on a key government committee that makes recommendations on the medical added value of new medicines. This appears to be the latest manifestation of the government's intent to proscribe all industry involvement in regulatory decision-making following the 2011 drug Mediator affairs.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.